Ozempic®, Wegovy®, Zepbound® Fatigue: Why Semaglutide and Tirzepatide Can Make You Tired

Medically authored by Joshua Silva, MD | Potere Health MD

SUMMARY GLP-1's and Fatigue.pdf

Download PDF • 144KB

• Yes, fatigue is a known side effect of semaglutide (Ozempic®, Wegovy®) and tirzepatide (Zepbound®/Mounjaro®).¹,²

• In clinical trials, fatigue occurred in ~11% of Wegovy users vs 5% placebo and ~5–7% of Zepbound users vs ~3% placebo.¹,²

• It is usually mild and may coincide with reduced intake, dehydration, or normal physiologic adaptation to sustained calorie deficit.⁵

• Fatigue management focuses on calorie intake, hydration, protein adequacy, activity, and dosing.

• Seek medical care for severe dizziness, fainting, chest pain, confusion, or persistent worsening fatigue.

---

Does Ozempic® or Wegovy® cause fatigue?

Yes. Fatigue is a documented adverse reaction to semaglutide.¹

According to FDA prescribing information for Wegovy® (semaglutide 2.4 mg):

• Fatigue (including asthenia) occurred in 11% of patients

• Compared with 5% in placebo-treated patients¹

• 
  

These figures are derived from large randomized controlled trials included in FDA labeling.¹

Ozempic® (semaglutide for diabetes) shares the same active ingredient, and fatigue is also reported in its safety data.¹

---

Does Zepbound® (tirzepatide) cause fatigue?

Yes. Fatigue is also reported with tirzepatide.²

In placebo-controlled obesity trials of Zepbound®:

• Fatigue (including fatigue, asthenia, lethargy, malaise) occurred in approximately 5–7% of patients depending on dose

• Compared with approximately 3% in placebo groups²

This confirms that fatigue is a recognized, quantified side effect of both GLP-1 and GLP-1/GIP therapies.¹,²

---

Why am I so tired on Ozempic®, Wegovy®, or Zepbound®?

The FDA labels confirm that fatigue occurs, but they do not attribute it to a single mechanism.¹,²

In clinical practice, fatigue often overlaps with common physiologic changes that occur during treatment:

1) Reduced Calorie Intake

GLP-1 medications suppress appetite and slow gastric emptying.¹

During sustained calorie deficits and weight loss, the body adapts by lowering total energy expenditure, including reductions in resting metabolic rate and spontaneous movement.

If calorie intake falls rapidly during dose escalation, temporary low energy may occur as the body adjusts to reduced fuel availability.

2) Inadequate Protein Intake

During calorie restriction and weight loss, insufficient protein intake increases the risk of lean mass loss and decreased physical function.³

Higher protein intake during weight loss has been shown to help preserve lean mass compared with lower protein intake.³

Protein is not a proven fatigue treatment, but adequate intake helps prevent under-nutrition–related low energy during active weight loss.

3) Dehydration or Electrolyte Imbalance

Both Wegovy® and Zepbound® include warnings about volume depletion and acute kidney injury related to dehydration, particularly in patients with significant vomiting or diarrhea.¹,²

Fatigue accompanied by dizziness, reduced urine output, or weakness may indicate dehydration rather than medication intolerance.

4) GI Side Effects Disrupting Intake or Sleep

Nausea, reflux, diarrhea, and constipation are among the most common GLP-1 adverse reactions.¹,²

If these symptoms reduce food intake or impair sleep, fatigue may follow.

---

Is fatigue from hypoglycemia? Usually not.

Semaglutide and tirzepatide rarely cause hypoglycemia when used alone.¹

The risk increases primarily when combined with insulin or sulfonylureas.¹

Hypoglycemia is typically episodic and presents with symptoms such as shaking, sweating, rapid heartbeat, confusion, or lightheadedness—not persistent low-grade fatigue.

If you are not taking insulin or a sulfonylurea, ongoing fatigue is unlikely to be caused by low blood sugar.

---

Is fatigue normal on GLP-1 medications?

Yes. Fatigue occurs in approximately 5–11% of patients in obesity trials.¹,²

In most cases, it is mild to moderate and does not lead to treatment discontinuation.¹,²

Severe fatigue is uncommon and should prompt further evaluation.

---

How long does GLP-1 fatigue last?

Clinical trial labeling does not specify exact duration.¹,²

However, fatigue is often reported during:

• Early treatment

• Dose increases

• Periods of rapid weight loss

Many patients improve as hydration and intake stabilize and the body adapts to the medication.

Persistent or worsening fatigue should be reviewed by a clinician.

---

What helps fatigue on Ozempic®, Wegovy®, or Zepbound®?

There are no randomized trials specifically studying “treatment of GLP-1 fatigue.” Management focuses on correcting common contributors:

1) Ensure Adequate Total Calorie Intake

GLP-1 medications reduce appetite.¹ During active weight loss, energy intake should be reduced — but not unintentionally driven too low.

Very low calorie intake can contribute to:⁵

• Low energy

• Reduced spontaneous activity

• Lightheadedness

• Weakness

The goal is a sustainable calorie deficit, not starvation.

Because appetite is suppressed, some patients unintentionally skip meals entirely. Structured small meals or protein-forward snacks may help maintain steady energy levels during the day.

If fatigue is persistent, reviewing overall intake with your clinician can help ensure calories are appropriate for your size and activity level.⁵

2) Hydration First

Maintain consistent fluid intake throughout the day.

Both Wegovy® and Zepbound® include warnings about volume depletion and acute kidney injury related to dehydration, particularly in patients with significant gastrointestinal adverse reactions.¹,²

If experiencing vomiting or diarrhea:

• Increase fluid intake

• Consider electrolyte replacement

• Monitor for dizziness, weakness, or reduced urination

Fatigue accompanied by these symptoms should prompt evaluation for dehydration rather than medication intolerance.

3) Ensure Adequate Protein Intake

Higher protein intake during weight loss helps preserve lean mass.³

Consensus guidance for adults during weight loss often supports approximately 1.0–1.2 g/kg/day, individualized based on age and activity level.⁴

Maintaining lean mass supports strength and physical function during calorie reduction.

4) Gradual Physical Activity

Regular physical activity has been shown to reduce fatigue and improve perceived energy levels in adults.⁶

Start gradually, especially if intake has recently decreased:

• Short walks

• Light resistance training

• Low-intensity movement spread throughout the day

During weight loss, activity also helps preserve lean mass and supports total daily energy expenditure.³

If fatigue is severe or accompanied by dizziness or dehydration, address hydration and calorie intake first before increasing activity.

---

When is fatigue not normal?

Urgent evaluation is recommended if fatigue occurs with:

• Severe dizziness or fainting

• Inability to maintain hydration

• Chest pain or shortness of breath

• Confusion

• Marked reduction in urine output

Both Wegovy® and Zepbound® labeling warn about dehydration-related kidney injury in the setting of significant GI adverse reactions.¹,²

---

Bottom Line

Fatigue is a recognized, quantified side effect of semaglutide and tirzepatide, occurring in approximately 5–11% of patients in clinical trials.¹,²

FDA prescribing information confirms fatigue occurs but does not identify a single mechanism.¹,² In practice, symptoms often overlap with reduced calorie intake, dehydration, or dose escalation, rather than medication toxicity.

Semaglutide and tirzepatide rarely cause hypoglycemia when used alone.¹ Ongoing fatigue in patients not using insulin or sulfonylureas is unlikely to be caused by low blood sugar.

Most cases improve with:

• Adequate total calorie intake

• Consistent hydration

• Sufficient protein during weight loss

• Gradual physical activity

• Appropriate dose stabilization

Severe, worsening, or persistent fatigue warrants medical evaluation.

---

Disclaimer

This article is for educational purposes only and is not a substitute for medical advice.

About the Author

Dr. Joshua Silva, MD, is a licensed physician and Medical Director of Potere Health MD. He earned his medical degree from the University of Hawaiʻi John A. Burns School of Medicine and completed residency training in Occupational and Environmental Medicine at the University of Utah, where he also earned a master’s degree in Occupational Health. He later completed a Master of Business Administration with an emphasis in health care administration at Ohio University.

Dr. Silva specializes in evidence-based weight management, including the careful monitoring and management of side effects such as fatigue during GLP-1 and GIP therapy with semaglutide and tirzepatide. He provides in-person and virtual care for patients in Salt Lake City, St. George, and Cedar City, Utah.

---

Sources

1. Novo Nordisk. Wegovy® (semaglutide) injection, prescribing information. Revised 2025. Accessed via FDA. Link

2. Eli Lilly and Company. Zepbound® (tirzepatide) injection, prescribing information. Revised 2025. Accessed via FDA. Link

3. Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;96(6):1281-1298. Link

4. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-559. Link

5. Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2010;34(Suppl 1):S47-S55. Link

6. Puetz TW, O’Connor PJ, Dishman RK. Effects of chronic exercise on feelings of energy and fatigue: a quantitative synthesis. Psychol Bull. 2006;132(6):866-876. Link